CoreCap Advisors’s Heron Therapeutics HRTX Stock Holding History

CoreCap Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$8.91K	Hold	28,409	–	–	﹤0.01%	2096
2026 Q2	$12.1K	Hold	28,409	–	–	﹤0.01%	1998
2026 Q1	$22.7K	Hold	28,409	–	–	﹤0.01%	1617
2025 Q4	$36.9K	Hold	28,409	–	–	﹤0.01%	1448
2025 Q3	$35.8K	Sell	28,409 -54	-0.2%	-$86	﹤0.01%	1443
2025 Q2	$58.9K	Sell	28,463 -123	-0.4%	-$251	﹤0.01%	1182
2025 Q1	$62.9K	Buy	28,586 +28,409	+16,050%	+$55.1K	﹤0.01%	1076
2024 Q4	$271	Buy	+177	New	+$287	﹤0.01%	2659
2022 Q4	$293	Buy	+117	New	+$377	﹤0.01%	2236
2022 Q3	–	Sell	-117	Closed	–	–	1197
2022 Q2	$0	Buy	+117	New	+$470	﹤0.01%	2196
2022 Q1	–	Sell	-117	Closed	-$1K	–	1207
2021 Q4	$1K	Buy	+117	New	+$1.2K	﹤0.01%	2139

Other funds holding HRTX

Congress Park Capital Saratoga Springs, New York $381M AUM 20.14% 1-Year Est. Return

Apeiron RIA Dallas, Texas $440M AUM 15.34% 1-Year Est. Return

Redwood Family Wealth Addison, Texas $113M AUM 24.54% 1-Year Est. Return

DLK Investment Management Solana Beach, California $275M AUM 10.69% 1-Year Est. Return

New Harbor Financial Group Worcester, Massachusetts $669M AUM 22.9% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

DDFG Inc Thousand Oaks, California $508M AUM 11.76% 1-Year Est. Return

Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

ACT Advisors Asheville, North Carolina $308M AUM 16.31% 1-Year Est. Return

Parkway Wealth Management Plano, Texas $869M AUM 25.74% 1-Year Est. Return

CoreCap Advisors's HRTX Position: Q3 2026 in Review

CoreCap Advisors held its Heron Therapeutics (HRTX) position steady in Q3 2026 at 28,409 shares worth $8.91K. The position accounts for ﹤0.01% of the portfolio, ranked #2096.

CoreCap Advisors first reported a position in HRTX in Q4 2021 and has held it in 11 quarters since. The position peaked at $62.9K in Q1 2025. 26 funds tracked by Wall St. Rank hold HRTX as of Q3 2026.

CoreCap Advisors held 28,409 shares of Heron Therapeutics worth $8.91K as of Q3 2026.
CoreCap Advisors left its Heron Therapeutics share count unchanged in Q3 2026.
Heron Therapeutics made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #2096 holding.
CoreCap Advisors first reported a position in Heron Therapeutics in Q4 2021 and has held it in 11 quarters since.
CoreCap Advisors's Heron Therapeutics position peaked at $62.9K in Q1 2025.
26 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.